Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Leukemia research
049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY.
Leukemia research
010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES.
Leukemia research
Study of the levels of expression of two oncogenes, c-myc and c-myb, in acute and chronic leukemias of both lymphoid and myeloid lineage.
Leukemia research
Differential patterns of expression of cell cycle-related genes in blast cells of acute myeloid leukemia.
Leukemia research
O-14 A reversible two-step model ofMDS/preleukemia: Transgenic mice expressing inducible BCL2 and mutant NRAS.
Leukemia research
Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice.
Leukemia research
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Leukemia research
The tortoise and the hare: slow and steady stem cells win the race.
Leukemia research